112641-23-3

Upstream product

• 13691-92-4 N-(4-chloro-3-trifluoromethylphenyl)-2,2-dimethylpropionamide 
• 74-88-4 methyl iodide 
• 3282-30-2 pivaloyl chloride 
• 320-51-4 4-chloro-3-trifluoromethyl-aniline 

Downstream Products

• 573762-19-3 4-chloro-2-methyl-3-(trifluoromethyl)benzenamine 
• 573764-81-5 N-(4-Cyano-2-methyl-3-trifluoromethylphenyl)-2,2-dimethyl-propionamide 
• 573764-86-0 4-amino-3-methyl-2-trifluoromethylbenzonitrile 
• 1371608-78-4 C₁₄H₁₁F₃N₂O₂ 
• 1371608-76-2 (R)-3-methyl-4-(2-oxo-5-((trityloxy)methyl)pyrrolidin-1-yl)-2-(trifluoromethyl)benzonitrile 
• 1371608-77-3 (R)-4-(2-(hydroxymethyl)-5-oxopyrrolidin-1-yl)-3-methyl-2-(trifluoromethyl)benzonitrile 
• 1371608-35-3 3-methyl-4-((R)-2-oxo-5-((S)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-2-(trifluoromethyl)benzonitrile 
• 1371608-36-4 3-methyl-4-((R)-2-oxo-5-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-2-(trifluoromethyl)benzonitrile 

Relevant academic research and scientific papers

FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

Provided are compounds according to any of Formula (I-1) to (I-7), pharmaceutical compositions comprising at least one of said compounds, their use as a medicament, and their use in treating chronic hepatitis B virus (HBV) infection. Methods for preparing compounds according to any of Formula (I-1) to (I-7) are also provided.

SELECTIVE ANDROGEN RECEPTOR MODULATORS

This invention provides compounds of formula I, pharmaceutical compositions comprising a compound of formula I and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds and intermediates useful in the preparation of same.

Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists

A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of hormone refractory prostate cancer. CH4933468 (32d) with a sulfonamide side chain not only exhibited antagonistic activity with no agonistic activity in the reporter gene assay but also inhibited the growth of bicalutamide-resistant cell lines. This compound also inhibited tumor growth of the LNCaP xenograft in mice dose-dependently.

NOVEL IMIDAZOLIDINE DERIVATIVES

Compounds represented by the general formula (I); and drugs and medicinal compositions, containing the compounds: (I) wherein n is an integer of 1 to 20; Q is (II) or (III) A is cyano or the like; B is hydrogen, halogeno, or the like; X1 and X

Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

Bicyclic modulators of androgen receptor function

The invention provides for a pharmaceutical composition capable of modulating the androgen receptor comprising a compound of formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia. Also provided are pharmaceutical compositions containing such compounds and processes for preparing some of the compounds of the invention.

BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION

The invention provides compounds according to formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia. Also provided are pharmaceutical compositions containing such compounds and processes for preparing some of the compounds of the invention.

Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions thereof

There are described compounds of Formula I, in which R1, R2, R3 and R4 are as defined in the specification,R5 is alkyl optionally interrupted by an amide group and optionally substituted by halogen or by a carboxy or a heterocyclic group,X is -O-, -NR-, -S(O)m1, or a bond,Z is hydrogen or together with R forms a bond,R is hydrogen, alkyl or together with Z forms a bond,R6 is a 5 or 6 membered unsaturated nitrogen containing heterocyclic ring, optionally fused to a phenyl ring and optionally substituted by one or more of oxo, hydroxy, alkyl, -(CH2)n1NH2, alkoxy, phenyl or -COOH,and when X is -NR- or -S(O)m1-, R6 may in addition be hydrogen or a group -CH2CH2NH2, -CH2CH2-het. or NHC(=NH)NH2,when X is -O-, R6 may also be a group -NH2, -C(=O) (CH2)nNH2, -CH2CH2NR14R15 or CH2CH2OCH2CH2NR14R15,when X is -NR-, -S(O)m1-, or a bond, R6 may also be hydrogen or a group -C(=NR12)NHR13,R13 and R14 may be hydrogen or alkyl,R12 is hydrogen, alkylcarbonyl, nitrile or hydroxy,R15 is hydrogen or a group R11,m and m1 are each 0, 1 or 2,n is 0 or 1,n1 is an integer from 0 to 6, and pharmaceutically acceptable salts, esters, amides, analogues and protected derivatives thereof.